Lucia Di Micco1, Robert Ross Quinn, Paul Everett Ronksley, Vincenzo Bellizzi, Adriane Marlene Lewin, Bruno Cianciaruso, Pietro Ravani. 1. Department of Medicine, Division of Nephrology, Hospital A. Landolfi, Solofra (AV), Italy;, †Departments of Medicine and Community Health Sciences, University of Calgary, Calgary, Alberta, Canada;, ‡Division of Nephrology, Dialysis and Transplantation, University Hospital San Giovanni di Dio e Ruggi d'Aragona, Salerno, Italy, §Department of Nephrology, University of Naples "Federico II," Naples, Italy.
Abstract
BACKGROUND AND OBJECTIVES: Twenty-four-hour urine creatinine excretion is a reliable approximation of muscle mass. Whether changes in urine creatinine predict clinical outcomes in persons with CKD is unknown. This work studied the relationship between urine creatinine and patient and renal survival in people with CKD not requiring renal replacement therapy. DESIGN, SETTING, PARTICIPANTS, & MEASUREMENTS: This longitudinal cohort study included incident stages 3-5 CKD patients referred to the renal clinic at the University Federico II in Naples between January of 1995 and December of 2005. Clinical data and urine creatinine were updated at each visit. Main outcomes were all-cause mortality and kidney failure requiring dialysis. RESULTS: This study enrolled 525 individuals and followed them for a median of 6 years (range of 4 months to 15 years). Urine creatinine excretion declined by 16 mg/d per year (95% confidence interval, 14 to 19) in participants with CKD stages 3a, 3b, and 4, and it remained stable in participants with stage 5 CKD. Per each 20 mg/d decline in urine creatinine, mortality increased by 3% (adjusted hazard ratio, 1.03; 95% confidence interval, 1.01 to 1.05), and the risk of initiating dialysis increased by 2% (adjusted hazard ratio, 1.02; 95% confidence interval, 1.01 to 1.03). These associations were independent of body mass index and GFR. CONCLUSIONS: In persons with CKD stages 3 and 4, urine creatinine declines at a rate of 16 mg/d per year. Lower urine creatinine excretion predicts greater risk of kidney failure and patient mortality.
BACKGROUND AND OBJECTIVES: Twenty-four-hour urine creatinine excretion is a reliable approximation of muscle mass. Whether changes in urine creatinine predict clinical outcomes in persons with CKD is unknown. This work studied the relationship between urine creatinine and patient and renal survival in people with CKD not requiring renal replacement therapy. DESIGN, SETTING, PARTICIPANTS, & MEASUREMENTS: This longitudinal cohort study included incident stages 3-5 CKD patients referred to the renal clinic at the University Federico II in Naples between January of 1995 and December of 2005. Clinical data and urine creatinine were updated at each visit. Main outcomes were all-cause mortality and kidney failure requiring dialysis. RESULTS: This study enrolled 525 individuals and followed them for a median of 6 years (range of 4 months to 15 years). Urine creatinine excretion declined by 16 mg/d per year (95% confidence interval, 14 to 19) in participants with CKD stages 3a, 3b, and 4, and it remained stable in participants with stage 5 CKD. Per each 20 mg/d decline in urine creatinine, mortality increased by 3% (adjusted hazard ratio, 1.03; 95% confidence interval, 1.01 to 1.05), and the risk of initiating dialysis increased by 2% (adjusted hazard ratio, 1.02; 95% confidence interval, 1.01 to 1.03). These associations were independent of body mass index and GFR. CONCLUSIONS: In persons with CKD stages 3 and 4, urine creatinine declines at a rate of 16 mg/d per year. Lower urine creatinine excretion predicts greater risk of kidney failure and patient mortality.
Authors: Leendert H Oterdoom; Ron T Gansevoort; Jan P Schouten; Paul E de Jong; Reinold O B Gans; Stephan J L Bakker Journal: Atherosclerosis Date: 2009-05-21 Impact factor: 5.162
Authors: Jozine M ter Maaten; Kevin Damman; Hans L Hillege; Stephan J Bakker; Stefan D Anker; Gerjan Navis; Adriaan A Voors Journal: Clin Res Cardiol Date: 2014-07-03 Impact factor: 5.460
Authors: F Perry Wilson; Dawei Xie; Amanda H Anderson; Mary B Leonard; Peter P Reese; Patrice Delafontaine; Edward Horwitz; Radhakrishna Kallem; Sankar Navaneethan; Akinlolu Ojo; Anna C Porter; James H Sondheimer; H Lee Sweeney; Raymond R Townsend; Harold I Feldman Journal: Clin J Am Soc Nephrol Date: 2014-11-07 Impact factor: 8.237
Authors: Elena Tynkevich; Martin Flamant; Jean-Philippe Haymann; Marie Metzger; Eric Thervet; Jean-Jacques Boffa; François Vrtovsnik; Pascal Houillier; Marc Froissart; Bénédicte Stengel Journal: PLoS One Date: 2014-11-17 Impact factor: 3.240
Authors: Harmke A Polinder-Bos; Hakan Nacak; Friedo W Dekker; Stephan J L Bakker; Carlo A J M Gaillard; Ron T Gansevoort Journal: Kidney Int Rep Date: 2017-03-10